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Background: In many countries, screening for colorectal cancer (CRC) relies on repeat testing using the guaiac faecal occult blood
test (gFOBT). This study aimed to compare gFOBT performance measures between initial and repeat screens.
Methods: Data on screening uptake and outcomes from the English Bowel Cancer Screening Programme (BCSP) for the years
2008 and 2011 were used. An existing CRC natural history model was used to estimate gFOBT sensitivity and specificity, and the
cost-effectiveness of different screening strategies.
Results: The gFOBT sensitivity for CRC was estimated to decrease from 27.35% at the initial screen to 20.22% at the repeat screen.
Decreases were also observed for the positive predictive value (8.4–7.2%) and detection rate for CRC (0.19–0.14%). Assuming
equal performance measures for both the initial and repeat screens led to an overestimate of the cost effectiveness of gFOBT
screening compared with the other screening modalities.
Conclusions: Performance measures for gFOBT screening were generally lower in the repeat screen compared with the initial
screen. Screening for CRC using gFOBT is likely to be cost-effective; however, the use of different screening modalities may result
in additional benefits. Future economic evaluations of gFOBT should not assume equal sensitivities between screening rounds.
Guaiac faecal occult blood tests (gFOBTs) are currently used to
screen for colorectal cancer (CRC) within England via the Bowel
Cancer Screening Programme (BCSP). This programme began
roll-out in 2006 employing biennial screening. Initially people aged
between 60 and 69 were eligible for screening, with the upper
age-limit later extended to 74 years. Within the United Kingdom,
CRC is the fourth most common form of cancer and the second
most common form of cancer-related mortality (Cancer Research
UK, 2013), with only half of all patients diagnosed with CRC
surviving for more than 5 years (National Cancer Intelligence
Network, 2013). Population-based screening for CRC is estimated
to be cost-effective (Whyte et al, 2012) and has the potential to
reduce CRC-related mortality due to earlier detection (and hence
treatment) of the disease (Hewitson et al, 2008). Results from the
first 1 million BCSP tests suggest that the programme is set to
reduce CRC-related mortality by 16% (Logan et al, 2012).
There are several different modalities for CRC screening
including: gFOBT, faecal immunochemical test for haemoglobin
(FIT), flexible sigmoidoscopy (FS) and colonoscopy. The choice
between screening modalities is determined by several factors:
feasibility (availability of resources, clinicians and infrastructure
to deliver the test to the population), acceptability (the
willingness of the population to take part), effectiveness
(determined by uptake, test sensitivity and specificity) and costs
(including test administration and follow-up, along with treat-
ment costs). Of these factors two key drivers are the specificity
and sensitivity, which indicate how accurately subjects with and
without the disease are classified by the screening test. Accurate
estimates of sensitivity and specificity are difficult to obtain and
they can vary considerably according to the population and the
method of test administration (Kraemer, 1985; Burch et al, 2007;
Leeflang et al, 2009).
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Initial screening refers to the first time a screening test is applied
to an individual, future applications of the screening test to the
same individual are referred to as repeat screens. An understanding
of how test performance varies between initial and repeat screens is
important to enable a robust comparison of screening strategies,
which involve repeated screening. Data from a number of
European countries suggest that, for screening programmes
involving gFOBT, the positive predictive value of screening for
both cancers and for adenomas decreases between the initial and
repeat screening rounds (Steele et al, 2010; Benson et al, 2012).
However, it is unknown whether these decreases between initial
and repeat screens relate to changes in the disease spectrum of the
population (the distribution of cancers and adenomas, as only a
nonrandom subset of those receiving an initial screen will receive a
repeat screen) or to changes in the test characteristics of sensitivity
and specificity between initial and repeat screening. Most studies
on the cost effectiveness of repeated gFOBT screening, including
the 2011 re-appraisal of the options for CRC screening in England
(Whyte et al, 2012), assume that gFOBT sensitivity and specificity
do not vary between screening rounds (Frazier et al, 2000; O’Leary
et al, 2004; Song et al, 2004; Wu et al, 2006; Macafee et al, 2008;
Tsoi et al, 2008; Heitman et al, 2010).
During the 2011 reappraisal, an unexpected difference between
model predictions and observed data was noted for the repeat
screen (Whyte et al, 2012). This difference motivated the current
study, which had two aims. The first was to investigate if gFOBT
performance measures, including sensitivity and specificity,
differed between initial and repeat screens. The second aim was
to assess the implications of any differences on the effectiveness
and cost-effectiveness of the different screening modalities that
may be used within the BCSP.
MATERIALS AND METHODS
Data used. Data were available from the BCSP for all persons
invited to screening in England between the years 2006 and 2011.
This comprises 9.8 million invitations to attend an initial screen of
which 4.6 million people were screened, and 2.0 million invitations
to attend a repeat screen of which 1.8 million people were screened.
A breakdown of the screening data by year is presented in Table 1.
Of those who were screened, data were available on the outcome of
the gFOBT screen, and, of those who were referred for follow-up,
data were available on whether any cancers or adenomas were
detected. It was hypothesised that during the initial roll-out of the
data there may have been a learning effect while the capacity to
deliver follow-up colonoscopy at a national level was established,
and that this may have affected the representativeness of the data.
Because of this, and because of the small number of repeat screens
in these 2 years, data for the first 2 years (2006 and 2007) were
excluded. The remaining data (from 2008 onwards) were used to
estimate detection rates and positive predictive values (PPV) for
CRC, low-risk and high-risk adenomas. Uptake and positivity rates
were also calculated. Where possible, performance measures were
based on those defined by the International Colorectal Cancer
Screening Network (Benson et al, 2012). Adenoma risk was on
based on British Society of Gastroenterology guidelines (Cairns
et al, 2010). Definitions for the measures used in this study are
provided in Box 1.
Colorectal cancer natural history model. An existing mathema-
tical model that represents the natural history of CRC along with
screening pathways was used to estimate sensitivity and specificity
and to also generate cost-effectiveness estimates. This model was
used for the 2011 re-appraisal of the options for screening in
England (Whyte et al, 2012), and synthesised incidence and
prevalence data and screening data from the BCSP, a UK trial of FS
(Atkin et al, 2010) and data on FIT from Italy (Castiglione et al,
2002). The model incorporates the benefits of screening from both
a reduction in incidence via the removal and surveillance of
adenomas, and a reduction in CRC mortality via earlier diagnosis
of CRC.
Estimates of the natural history of CRC progression from
normal colorectal epithelium through the development of
adenomas, CRC and eventual mortality were obtained, as were
the performance measures of sensitivity and specificity for each of
the screening modalities. Health-care resource use and costs, along
with the impact on patient’s health-related quality of life were
evaluated for a range of screening options. Full technical details
have been previously published (Whyte et al, 2011a, 2012) and
details relevant to this study are described below.
The model is a cohort–Markov model built in Microsoft Excel,
which simulates both the natural history of CRC and the possible
pathways of screening participants, as shown in Figure 1. Accurate
observational data for natural history transition rates and for
sensitivity and specificity were not available, so Bayesian calibra-
tion methods were used to jointly estimate these (Whyte et al,
2011b). These unobserved parameters were linked to observed
outcomes via the CRC natural history model, the calibration
methods searched over possible parameter values, and selected
those which best fit the observed data. Screening outcomes for an
individual depend on both their underlying natural history and the
effectiveness of the screening modality. This effectiveness was
measured by a number of performance measures, which consists of
sensitivity, specificity, PPV, uptake, positivity, and detection rates
for CRC, high-risk adenomas and low-risk adenomas. The model
allowed estimates of sensitivity to vary by disease severity and
estimates of specificity to vary by age.
Table 1. Breakdown of screening data available from the English Bowel Cancer Screening Programme, by year
Initial screen Repeat screen
Year Invited Screened Uptake % Invited Screened Uptake %
2006 54 779 28051 51 o5 0 0
2007 740 890 380659 51 788 303 38
2008 1956 674 1 020008 52 16147 13981 87
2009 2238 854 1 141565 51 242540 208049 86
2010 2483 968 1 147347 46 813549 710632 87
2011 2374 449 909389 38 970350 854437 88
Total 9 849 614 4 627019 47 2 043374 1 787402 87
2008 to 2011 9053 945 4 218309 47 2 042586 1 787099 87
Colorectal cancer; initial and repeat screens BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.469 1735
For this analysis, the model was adapted and re-calibrated to
allow performance measures to vary between initial and repeat
screens. It was assumed that all repeat screens had equal
performance measures. Variations in performance measures by
age were also explored, to assess if any between-round differences
were specific to any age groups.
Statistical methods. To convey an assessment of uncertainty, 95%
confidence intervals were calculated. All of the intervals are based
on the Wilson method (Newcombe, 2012). The differences
between the initial and repeat screens were tested for statistical
significance using the two-proportion Z-test. Evidence of an age
gradient was assessed by fitting linear regression models (weighted
by the number of observations). A P-value less than 0.05 was
deemed to be statistically significant.
Effectiveness and cost effectiveness. The results from the adapted
and re-calibrated model were used to estimate the cost effectiveness
of various CRC screening options. This study considered the same
screening options as the 2011 re-appraisal, which includes the
modalities gFOBT, FIT, FSIG and combinations. Effectiveness was
measured in terms of CRC cases avoided and lives saved. Cost
effectiveness was measured as the incremental cost per incremental
quality-adjusted life year (QALY) gained. The analysis took the
perspective of the NHS and personal social services in England.
Both costs and QALYs were discounted at a rate of 3.5% per year,
as recommended by the National Institute for Health and Care
Excellence (2013). A lifetime horizon was employed.
RESULTS
Between 2008 and 2011, a total of 9 053 945 first invitations for an
initial screen were sent out, along with 2 042 586 first invitations
for a repeat screen. Performance measures for the initial and repeat
screens are displayed in Table 2. All of the differences were
statistically significant (Po0.001). Uptake, positivity rate, detection
rate and PPVs are based on observed data from the BCSP, while
sensitivity and specificity are estimated via the model calibration
process. For sensitivity and specificity, the estimated values were
used to derive the denominator value.
Performance measures derived directly from observed data.
During the initial screen a total of 4 218 309 useable kits were
returned, producing an uptake of 46.59% (95% confidence interval
46.56–46.62%). This figure increased to 87.49% (87.45–87.54%) for
the repeat screen. Of those who responded to initial screening
using gFOBT, 93 355 had a positive result requiring further
investigation, giving a positivity rate of 2.21% (2.20–2.23%) for the
initial screen, which dropped to 1.97% (1.96–1.20%) for the repeat
screen.
Detection rates for both CRC and high-risk adenomas were
both higher for the initial screen than for the repeat screen.
CRC=colorectal cancer, LR=low risk, HR=high risk 
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Figure 1. Schematic of the natural history model for CRC and the screening pathways, as used for this study. Reproduced with permission from
Whyte et al (2012).
Box 1 Definitions used within this study
Initial screen: The first time a person is screened.
Repeat screen: A screen in a person who has previously been screened.
Small adenoma: an adenoma that is less than 1 cm.
Low-risk adenomas health state: people with one or two small adenomas.
High-risk adenomas health state: people with at least three small
adenomas, or at least one adenoma greater than 1cm.
Uptake: the number of results obtained for a test divided by the number of
invitations.
Positivity: the number of people with a positive test results (those persons
referred to follow-up colonoscopy) divided by the total number of test results.
Adenoma (or CRC) detection rates: the number of people with adenomas
(or CRCs) detected by a test, divided by the tested population.
Positive predictive value for adenomas (or CRC): the proportion of positive
test results that were shown to be an adenoma (or CRC) at colonoscopy.
Sensitivity to adenomas (or CRC): the probability that a test gives a
positive result amongst people with adenomas (or CRC).
Specificity to adenomas (or CRC): the probability that a test gives a
negative result amongst people without adenomas (or CRC).
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For CRC, the detection rate fell by over a quarter (in relative terms)
from 0.185 (0.181–0.189%) to 0.141% (0.136–0.147%), a similar
(relative) decrease was observed for high-risk adenomas, from
0.542 (0.535–0.549%) to 0.393% (0.384–0.402%).
Colorectal cancer was identified in 7805 of respondents with a
positive gFOBT during the initial screen, giving a PPV of 8.36%
(8.19–8.54%), which fell to 7.16% (6.89–7.43%) during the repeat
screen. The PPVs for high-risk adenoma also decreased, from
24.49 (24.22–24.77%) to 19.91% (19.50–20.33%).
Performance measures estimated using mathematical model.
The sensitivity of gFOBT to detecting CRC during the initial screen
was estimated to be 27.35% (26.84–27.87%), dropping to 20.22%
(19.53–20.93%) for the repeat screen. A similar pattern is seen for
high-risk adenomas; sensitivity drops from 13.51% (13.35–13.67%)
during the initial screen to 9.46% (9.26–9.68%) during the repeat
screen.
Estimated specificity values varied by age, for every increase in
age by 1 year, specificity decreased by 0.03% in the initial screen
and by 0.04% in the repeat screen. Estimated specificities for the
ages 65 and 70 years are presented as examples. During the initial
screen the estimates were 97.92% (97.86–97.98%) for age 65 and
97.77% (97.55–97.98%) for age 70 years. For the repeat screen,
these values were 97.31% (97.23–97.40%) and 97.13% (97.03–
97.24%), respectively.
Variations in gFOBT performance measures by age at initial
and repeat screen. Variation by age in uptake and detection rates
are displayed in Figure 2, while differences in positivity rate and
PPVs are displayed in Figure 3.
The results presented in Figures 2 and 3 show that the
(statistically significant) differences between initial and repeat
screen are observed for all of the age groups, and are not caused by
differences amongst age subgroups. The figures also emphasise that
there were relatively small numbers of individuals aged over 70
years in the screening programme (for both rounds) and a small
number of individuals aged 61 years receiving a repeat screen, as
reflected by the wide confidence intervals among these ages.
There was no evidence of a statistically significant age gradient
for uptake rates or for low-risk adenoma PPVs at either screen. All
of the other performance measures had statistically significant age
gradients for both screens. These conclusions remained the same
when individuals aged above 70 years were excluded from the
analysis.
Impact on cost effectiveness. Estimates of cost effectiveness for 13
different screening options are presented in Table 3. Results are
discounted per person over their lifetime and ordered by increasing
costs. A strategy of no screening is the cheapest, but also results in
the fewest QALYs. Of the strategies involving only a single
modality, those involving FIT dominate those involving either
gFOBT or FS. The hybrid strategy of FS at age 55 years followed by
biennial FIT between the ages of 60 and 74 years is the most
effective (generates the most QALYs), but is also more expensive
than any of the strategies involving FIT alone. Uncertainty in these
results was assessed using probabilistic sensitivity analyses (as
described in the previous re-appraisal (Whyte et al, 2012)), and
was found to be small.
Compared with no screening, a strategy of biennal gFOBT
screening between the years of 60 and 69 is estimated to generate
an additional 0.005 QALYs, at an additional cost of d12, resulting
in an incremental cost-effectiveness ratio (ICER) of d2420.
Extending the upper age-limit to 74 increases this ICER to
d2900. Both of these values are comfortably below the threshold of
d20 000 often used to determine cost effectiveness at a national
level. By not modelling differences in gFOBT test characteristics at
repeat screens, the cost effectiveness of gFOBT screening is
overestimated. There is no difference in average costs, but for
biennial gFOBT at age 60–69 the average QALYs accrued increases
Table 2. Observed and estimated performance measures (values given as percentages and the corresponding denominator (n) value), along with a 95%
confidence interval
Initial screen % (n)
(95% CI)
Repeat screen % (n)
(95% CI)
Performance measures derived directly from observed data
Uptake 46.591 (9 053 945) (46.558 to 46.623) 87.492 (2 042 586) (87.447 to 87.537)
Positivity rate 2.213 (4 218 309) (2.199 to 2.227) 1.975 (1 787 099) (1.955 to 1.995)
Detection rates
Colorectal cancer 0.185 (4 218 309) (0.181 to 0.189) 0.141 (1 787 099) (0.136 to 0.147)
High-risk adenomas 0.542 (4 218 309) (0.535 to 0.549) 0.393 (1 787 099) (0.384 to 0.402)
Low-risk adenomas 0.308 (4 218 309) (0.302 to 0.313) 0.316 (1 787 099) (0.307 to 0.324)
Positive predictive value
Colorectal cancer 8.361 (93 355) (8.185 to 8.540) 7.157 (35 295) (6.893 to 7.430)
High-risk adenomas 24.494 (93 355) (24.219 to 24.771) 19.909 (35 295) (19.496 to 20.329)
Low-risk adenomas 13.896 (93 355) (13.676 to 14.120) 15.977 (35 295) (15.598 to 16.363)
Performance measures estimated using mathematical model
Sensitivity
Colorectal cancer 27.349 (28 538) (26.835 to 27.869) 20.220 (12 492) (19.525 to 20.934)
High-risk adenomas 13.508 (169 280) (13.346 to 13.671) 9.463 (74 254) (9.255 to 9.676)
Low-risk adenomas 1.114 (1 164 489) (1.095 to 1.133) 1.084 (520 078) (1.056 to 1.113)
Specificity
Age 65 97.922 (238 419) (97.864 to 97.979) 97.314 (139 728) (97.228 to 97.398)
Age 70 97.773 (18 693) (97.552 to 97.975) 97.133 (99 120) (97.027 to 97.235)
Abbreviations: CI¼ confidence interval; CRC¼ colorectal cancer.
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to 19.060, resulting in an ICER of d1922 compared with no
screening. For biennial gFOBT at age 60–74 the average QALYs
accrued increases to 19.062, resulting in an ICER of d2213
compared with no screening.
DISCUSSION
The results of this study show the performance of the English
gFOBT BCSP against a number of key performance measures for
both initial and repeat screens. There was an increase in uptake
rates for the repeat screen compared with the initial screen.
However, for CRC and for high-risk adenomas, the performance
measures of sensitivity, specificity, PPV and detection rate were all
lower in the repeat screen compared with the initial screen. There
was little difference in these performance measures for low-risk
adenomas.
For cancer screening programmes, uptake rates have been
identified as key measures (Steele et al, 2009). An overall uptake of
47% for the initial screen was observed in this study, which
compares with an uptake of 87% for the repeat screen. A lower
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Figure 2. (A) Variation in uptake rate by age, (B) Variation in low-risk adenoma detection rate by age, (C) Variation in high-risk adenoma
detection rate by age, (D) Variation in colorectal cancer detection rate by age. For all, 95% confidence intervals are displayed, although for some
data points these are not noticeable due to their short width.
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uptake rate for initial screening (compared with repeat screening)
is to be expected, as initial screening is offered to the entire eligible
population, whereas repeat screening is only offered to people who
previously accepted screening, and so are likely to accept a repeat
screen (Janda et al, 2010). Uptake rates for initial screening will
also be affected if there exists a subgroup of ‘persistent refusers’ in
the eligible population.
For both CRC and high-risk adenomas, there was a drop in
detection rates, PPVs and sensitivities between the initial and
repeat screens. Similar decreases have been observed for gFOBT
screening programmes across the world (Benson et al, 2012).
A limited number of studies have estimated how the sensitivity of
gFOBT varies between screening rounds. The UK (Nottingham)
pilot (Moss et al, 1999) (which used biennial screening), using
the proportional incidence method (Day, 1985), reported CRC
sensitivities of 62.7% for the first screen and 50.0% for the
rescreen. A method based on the number of observed interval
cancers was applied to data from the Province of Florence to give
CRC sensitivities of 38% for the first screen and 62% for
subsequent screens (Zappa et al, 2001). There is a large degree of
variation in both the estimates of CRC sensitivity and the
methods used to derive them. The use of interval cancers to
estimate sensitivity has two main limitations; first, some interval
cancers would not have been cancers at the time of the screen and
second, not all undetected cancers will be diagnosed within any
given interval. The proportional incidence method alleviates the
first limitation by replacing interval cancers with the incidence of
cancers in the absence of screening. However, it does not
explicitly consider the second limitation. The values presented
here are based on explicitly modelling the natural history of CRC
in the absence of screening, and so address both of these
limitations. The CRC sensitivities reported in this study (27% for
the first screen and 20% for the repeat screen) are lower than the
estimates from the UK pilot and the Province of Florence
estimates. This is likely to be due to the slow-growth rate of early-
stage cancers, which may not present symptomatically for a number
of years. For example, one study found an overall FOBT sensitivity
to CRC of 12.9%, which fell to 6.7% for TNM Stage I cancers
(Imperiale et al, 2004). It should also be noted that the sensitivity
estimates reported for this study relate to an individual screen,
gFOBT screening is carried out on a biennial basis within the BCSP,
so the overall programme sensitivity will be much higher.
Decreases in detection rates and PPV at the repeat screen may
be due to the initial screen reducing the prevalence of CRC and
high-risk adenomas among people attending for repeat screening,
without reducing the false-positive rate (Steele et al, 2010). This
effect should not lead to changes in sensitivity and specificity as
these two measures are theoretically independent of underlying
disease prevalence. However, it has been shown in practice that
changes in disease spectrum can affect sensitivity and specificity
(Kraemer, 1985; Leeflang et al, 2009). Differences in CRC and
adenoma prevalence at the initial and repeat screens were included
within the natural history model, hence these differences alone did
not explain the decrease in gFOBT test performance. It is possible
that other changes in disease spectrum that lead to the decrease in
PPVs and detection rates observed in this study may also have led
to the estimated decreases in sensitivity and specificity. In addition
to a lower CRC prevalence at repeat screening, there may also be
other disease spectrum differences. For example, completed gFOBT
samples are classified as abnormal or normal depending on the
presence or absence of blood in the faecal samples. It may be
hypothesised that patients with heavy bleeding are more likely to
be detected in the first round, which would lead to a decrease in
detection rates for repeat screening.
The cost effectiveness of different screening strategies for CRC
was re-assessed using different test characteristics for the initial
and repeat rounds of gFOBT. The results indicated that screening
with FIT (possibly preceded by FS) was to be preferred to screening
with either gFOBT, FS or a combination of the two. It should be
stressed that the choice of screening modality depends on more
than just the cost-effectiveness results, as other criteria such as the
feasibility and acceptability of each modality must also be
considered. While the BCSP currently uses biennial gFOBT
screening, screening with FIT (Logan et al, 2012) is being
evaluated, and FS is currently being piloted.
There are a number of existing economic evaluations of the cost
effectiveness of gFBOT screening for CRC (Lansdorp-Vogelaar
et al, 2011), covering areas such as the United States (Frazier et al,
2000), United Kingdom (Macafee et al, 2008), Australia (O’Leary
et al, 2004), France (Berchi et al, 2004) and Asia (Tsoi et al, 2008).
There are differences between these economic evaluations due to
variations in screening programmes between countries. These
differences include the use of private health care in the United
States of America and the use of different screening algorithms,
Table 3. Comparison of the cost effectiveness of different screening modalities
Strategy Costs QALYs ICER Comparator
No screening d78 19.054
gFOBT at 60–69 (biennial) d90 19.059 Ext. Dom. FIT at 60, 65, 70 years
gFOBT at 60–74 (biennial) d95 19.060 Ext. Dom. FIT at 60, 65, 70 years
FIT at 60, 65, 70 years d96 19.062 d2150 No screening
FIT at 60–69 (biennial) d107 19.066 d3002 FIT at 60, 65, 70 years
FIT at 60–74 (biennial) d120 19.069 d5658 FIT at 60–69 (biennial)
FS at age 55 d182 19.060 Dominated FIT at 60–74 (biennial)
FS age 55, gFOBT 66–74 (biennial) d192 19.063 Dominated FIT at 60–74 (biennial)
FS age 55, FIT 60, 65, 70 d200 19.067 Dominated FIT at 60–74 (biennial)
FS age 55, FIT 66–74 (biennial) d208 19.067 Dominated FIT at 60–74 (biennial)
FS age 55, FIT 60–74 (biennial) d224 19.072 d27,868
FS age 55, FIT 56–74 (biennial) d236 19.054 Dominated FIT at 60–74 (biennial)
FS age 55, 65 d253 19.065 Dominated FIT at 60–74 (biennial)
Abbreviations: gFOBT¼guaiac faecal occult blood test; FIT: faecal immunochemical test for haemoglobin, FS: flexible sigmoidoscopy. ICER: Incremental cost-effectiveness ratio. Ext. Dom.:
extendedly dominated. Intervention A is dominated by intervention B if the latter is cheaper and produces more QALYs. Intervention A is dominated by intervention B if the latter is cheaper
and has a lower ICER. Currently used strategy is shown in italics.
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including different test thresholds for referral (Benson et al,
2012). However, it is important to note that all of these existing
economic evaluations have assumed that the performance
measures of gFOBT sensitivity and specificity are the same
across screening rounds. The results of this study indicate that
this may not be the optimal approach, and that more realistic
estimates of the effectiveness of gFOBT would be obtained by
modelling separate performance measures across screening
rounds.
Owing to a lack of available data, when calculating the cost
effectiveness results for this study it was assumed that all repeat
screens had equal test characteristics (such as sensitivity).
In addition, it was also assumed that performance measures
for FIT screening were the same for the initial and repeat
screens.
There are a number of strengths to this study. The BCSP
provides a large volume of data covering all of England, allowing
for accurate estimates of the observed performance indicators
(uptake, detection rates, and PPVs). Use of a mathematical model
allows for the comparison of screening programmes based on
different evidence sources within a consistent framework, and
permits the estimation of unobservable quantities such as the
natural history of CRC in the absence of screening. The
mathematical model previously assumed equal test characteristics
between screening rounds. This structural uncertainty was
explored in this study by allowing the screening test characteristics
to vary between initial and repeat screens. Comparing different
model structures helps to provide a greater understanding of the
natural history of CRC and how this interacts with the screening
test characteristics.
In summary, this study has shown that both observed and
estimated performance measures show a decrease when comparing
initial and repeat screening. The results presented here indicate
that screening for CRC is still likely to represent a cost-effective
strategy, but also that there is room for further development, for
example by exploring the use of different screening modalities. The
results from this study suggest that future evaluations of gFOBT
screening should not assume equal test characteristics (such as
sensitivity and specificity) between screening rounds.
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